Buscar
Mostrando ítems 1-10 de 1209
New Cannabinoid receptor type 1 and 2 agonists and applications to understanding the endocannabinoid system: A chemical approach
(Academic Press, 2023)
The modulation of the endocannabinoid system by synthetic ligands has allowed mediating several pathophysiological processes in the control of various diseases. The work of many chemists in designing drugs that activate ...
Non-equivalent ligand selectivity of agonist sites in (α4β2) 2α4 nicotinic acetylcholine receptors: A key determinant of agonist efficacy
(American Society for Biochemistry and Molecular Biology Inc., 2014)
The α4β2 nicotinic acetylcholine receptor (nAChR) is the most abundant nAChR type in the brain, and this receptor type exists in alternate (α4β2)2α4 and (α4β2)2β2 forms, which are activated by agonists with strikingly ...
New Pyridone-Based Derivatives as Cannabinoid Receptor Type 2 Agonists
(MDPI, 2021)
The activation of the human cannabinoid receptor type II (CB2R) is known to mediate analgesic and anti-inflammatory processes without the central adverse effects related to cannabinoid receptor type I (CB1R). In this work ...
Non-equivalent ligand selectivity of agonist sites in (alpha 4 beta 2)(2)alpha 4 nicotinic acetylcholine receptors a key determinant of agonist efficacy
(AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2014)
A conserved arginine with non‐conserved function is a key determinant of agonist selectivity in α7 nicotinic ACh receptors
(Wiley Blackwell Publishing, Inc, 2021-04)
The α7 and α4β2* (“*” denotes possibly assembly with another subunit) nicotinic acetylcholine receptors (nAChRs) are the most abundant nAChRs in the mammalian brain. These receptors are the most targeted nAChRs in drug ...
Diverging mechanisms of activation of chemokine receptors revealed by novel chemokine agonists
(Public Library of Science, 2011)
CXCL8/interleukin-8 is a pro-inflammatory chemokine that triggers pleiotropic responses, including inflammation, angiogenesis, wound healing and tumorigenesis. We engineered the first selective CXCR1 agonists on the basis ...